Kim D. Janda
Director/Board Member chez SORRENTO THERAPEUTICS, INC.
Fortune : - $ au 31/03/2024
Profil
Kim D.
Janda is the founder of CombiChem, Inc., Drug Abuse Sciences.
He is currently the Director at Sorrento Therapeutics, Inc., Worm Institute For Research & Medicine, Cessation Therapeutics, LLC, and Professor at The Scripps Research Institute.
He holds a doctorate degree from the University of Arizona and an undergraduate degree from the University of South Florida.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 31/01/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Kim D. Janda
| Sociétés | Poste | Début |
|---|---|---|
| SORRENTO THERAPEUTICS, INC. | Director/Board Member | 01/04/2012 |
The Scripps Research Institute
 The Scripps Research Institute Other Consumer ServicesConsumer Services The Scripps Research Institute is a private, non-profit research organizations that performs basic biomedical research in molecular & cellular biology, chemistry, immunology and neuroscience. They receive the majority of its funding from federal agencies such as the National Institutes of Health. The organization also partners with pharmaceutical companies and is affiliated with the Scripps hospital group. The organization was founded in 1955 and is headquartered in La Jolla, California. | Corporate Officer/Principal | 01/01/1996 |
| Worm Institute For Research & Medicine | Director/Board Member | 01/01/2005 |
Cessation Therapeutics, LLC
 Cessation Therapeutics, LLC Pharmaceuticals: MajorHealth Technology Cessation Therapeutics, LLC is a clinical-stage pharmaceutical company that develops immunobiologics to prevent and protect against overdose. The company is based in San Jose, CA. The company's monoclonal antibodies are designed to target fentanyl and future synthetic opioids and other substances. The company has the potential to treat a range of substance use disorders and improve the lives of patients and families affected by the addiction crisis. Cessation was founded in 2018 by Mark Pearson and John D. Harkey, Jr., experienced, successful long-term biotech investors. The CEO is Mark E. Pearson. | Director/Board Member | - |
Anciens postes connus de Kim D. Janda
| Sociétés | Poste | Fin |
|---|---|---|
| Drug Abuse Sciences | Founder | - |
CombiChem, Inc.
 CombiChem, Inc. Miscellaneous Commercial ServicesCommercial Services CombiChem, Inc. used to provide computational drug recovery services to accelerate the discovery process for new drugs and chemical compounds. The company was founded in 1994 and headquartered in San Diego, CA | Founder | - |
Formation de Kim D. Janda
| University of Arizona | Doctorate Degree |
| University of South Florida | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| SORRENTO THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
CombiChem, Inc.
CombiChem, Inc. Miscellaneous Commercial ServicesCommercial Services CombiChem, Inc. used to provide computational drug recovery services to accelerate the discovery process for new drugs and chemical compounds. The company was founded in 1994 and headquartered in San Diego, CA | Commercial Services |
| Drug Abuse Sciences | |
Cessation Therapeutics, LLC
Cessation Therapeutics, LLC Pharmaceuticals: MajorHealth Technology Cessation Therapeutics, LLC is a clinical-stage pharmaceutical company that develops immunobiologics to prevent and protect against overdose. The company is based in San Jose, CA. The company's monoclonal antibodies are designed to target fentanyl and future synthetic opioids and other substances. The company has the potential to treat a range of substance use disorders and improve the lives of patients and families affected by the addiction crisis. Cessation was founded in 2018 by Mark Pearson and John D. Harkey, Jr., experienced, successful long-term biotech investors. The CEO is Mark E. Pearson. | Health Technology |
